Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Assembly of B. pseudomallei proteins to virus-like particles as a vaccine platform against melioidosis

Award Number: R21AI189278
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/02/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2028

Group Awards By:

View Award Description

Assembly of B. pseudomallei proteins to virus-like particles as a vaccine platform against melioidosis - PROJECT SUMMARY/ABSTRACT There is a gap in the development of effective therapeutic approaches targeting under-studied pathogens that can cause human disease, such as Burkholderia pseudomallei (Bpm), the causative agent of melioidosis. The impact of Bpm on public health has escalated because areas considered non-endemic, including now the continental USA, have tested positive, with a corresponding increase in human cases and fatalities. In addition to classifying the pathogen as a biological select agent, the increased number of diabetic and immunosuppressed patients, two growing populations worldwide, justifies the importance of developing a vaccine intervention as a public health measure. Therefore, we argue that the development of a safe and effective vaccine would protect at-risk populations in endemic areas or those individuals susceptible to acquiring the pathogen naturally or as part of a man-made biological threat. Our long-term goal is to develop new strategies in the development of vaccines that can fully protect against Bpm isolates, while elucidating its protective immune responses, information that will be incorporated in the development of other vaccines against different pathogenic Burkholderia species. Our approach uses proven protective Bpm antigens coupled to virus-like particles (VLPs) as vaccines while evaluating effectiveness using clinically relevant mice models of melioidosis. The central hypothesis is that proven protective antigens coupled with VLPs will induce robust immune responses eliciting protective immunity against melioidosis disease. Together, the outcomes of our application will prove that our novel VLP-Bpm-antigen vaccines will induce strong protective immune responses against disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $200,000 )
2026	2026	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	1	7/6/2026	NEW	$200,000
														Subtotal = $200,000

Grand Total All Awards = $200,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Assembly of B. pseudomallei proteins to virus-like particles as a vaccine platform against melioidosis

Award Number: R21AI189278

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/02/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2028

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer